In parallel with the prelim clinical data from the three trials in different indications, there will be the pre-clinical data from CDH17 expressing solid tumours via both Autologous Car-T and Allogeniec Car-NK. All eyes in the industry will be on CHM and hence why (perhaps) the timing and preemptive CR plan.
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial, page-25
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.001(11.1%) |
Mkt cap ! $9.751M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $41.55K | 4.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1934891 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 2853536 | 6 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |